Company**

Product

Description

Indication

Status (Date)

CANCER

Antisoma plc (U.K.; EASDAQ: ASOM)

Theragyn

Murine monoclonal antibody HMFG1, linked to yttrium-90

Adjuvant treatment of ovarian cancer

Updated Phase II trial at the 46th Annual Meeting of the U.S. Society of Nuclear Medicine in Los Angeles (6/9)

Atrix Laboratories Inc.

­

Atrigel formulation of leuprolide acetate; drug is delivered via biodegradable polymeric sustained-release formulation

Prostate cancer

Completed Phase I trial (6/3)

AVI Biopharma Inc.

Avicine

Synthetic c-terminal peptide of human chorionic gonadotropin, conjugated to diphtheria toxoid to enhance immuno-genicity

Pancreatic cancer

Announced plan to initiate Phase II trial on 6/15 (6/2)

Bioenvision Inc. (U.K.; OTC BB:BIOV)

­

Clofarabine; immunosuppressive agent that also inhibits DNA repair

Leukemia, lymphoma and solid tumors

Presented Phase I trial results at the 4th Annual Meeting of the European Hematology Association in Barcelona, Spain (6/23)

Cerus Corp.

ACIT system (allogeneic cellular immune therapy)

Donor T-cells are treated with light-activated psoralen compound, S-59, as an adjunct to haploidentical (half-matched) bone marrow transplants

Prevention of grafte vs. host disease and other serious adverse reactions to bone marrow transplant

Initiated Phase I study (6/30)

Diatide Inc.

NeoTect

Small-molecule synthetic peptide labeled with technetium-99m; peptide designed to adhere to somatostatin receptor

Detection of solitary pulmonary nodules, a prevalent form of lung cancer

Presented data from Phase III trial at the Society of Nuclear Medicine Meeting in Los Angeles (6/7)

FeRx Inc.*

MTC-DOX

Doxorubicin delivered via Magnetic Targeted Carrier sustained-release technology

Primary liver cancer

Initiated Phase I/II trial (6/4)

LeukoSite Inc. and ILEX Oncology Inc.

Campath-1H

Humanized monoclonal antibody that specifically targets and binds to CD52 cell surface antigen on lymphocytes

Chronic lymphocytic leukemia refractory to fludarabine

Presented pivotal Phase II data at the Annual Meeting of the European Hematology Association in Barcelona, Spain (6/9)

Ligand Pharmaceuticals Inc.

Targretin capsules

Bexarotene; synthetic retinoid analogue that selectively activates retinoid X receptors; oral formulation

Early-stage cutaneous T-cell lymphoma

Released pivotal trial data in conjunction with NDA submission (6/23)

INEX Pharmaceuticals Inc.

Onco TCS

Formulation of vincristine encapsulated in company's Transmembrane Carrier System

Relapsed non-Hodgkin's lymphoma

Presented further results from Phase IIa trial at 7th International Conference on Malignant Lymphoma in Lugano, Switzerland (6/7)

Inflazyme Pharmaceuticals Ltd.* (Canada) and Hoechst Marion Roussel (unit of Hoechst AG; Germany)

IPL576,092

Anti-inflammatory agent based on molecule originally isolated from a sea sponge

Asthma

Initiated Phase I studies (6/2)

Introgen Therapeutics Inc.* and RPR Gencell division of Rhone-Poulenc Rorer Inc. (NYSE:RP)

RPR/INGN 201

Intravenous administration of adenoviral-delivered p53 gene

Nonresectable solid tumors unresponsive to prior therapy

Initiated Phase I trial (6/2)

LifeTime Pharmaceuticals* and Dovetail Technologies Inc.*

Beta LT

Beta-alethine; synthetic small-molecule immune stimulator

Multiple myeloma

Reported enrollment of first 3 patients (6/29)

Magainin Pharmaceuticals Inc.

Squalamine

Synthetically produced version of a compound found in the dog-fish shark; anti-angiogenic compound combines a steroid and a polyamine (intravenous)

Advanced non-small-cell lung cancer (combination trial with paclitaxel and carboplatin)

Initiated Phase II trial (6/24)

Matrix Pharmaceutical Inc.

Intradose Injectable Gel

Biodegradable gel combining cisplatin and epinephrine (intratumoral injection)

Primary liver cancer

Completed enrollment in Phase II trial (6/7)

Osiris Therapeutics Inc.*

Allogen

Infused, donor-derived adult mesenchymal stem-cell product

Prevention of graft rejection or graft vs. host disease in patients undergoing high-dose chemotherapy and hematopoietic stem-cell transplantation

Initiated safety trial (6/8)

SafeScience Inc.

GBC-590

Designed carbohydrate lectin inhibitor that competitively binds to unique lectins on cancer cells and disrupts the metastatic process

Relapsing, resistant prostate cancer

Completed Phase I/II trial and initiated Phase II trial (6/24)

SafeScience Inc.

GBC-590

Designed carbohydrate lectin inhibitor that competitively binds to unique lectins on cancer cells and disrupts the metastatic process

Pancreatic cancer

Initiated Phase I/II trial (6/24)

Techniclone Corp.

Cotara (formerly TNT)

Tumor necrosis therapy; chimeric monoclonal antibody that targets DNA-associated histone antigens, labeled with I-131 (targets necrotic center of tumor)

Pancreatic, prosstate and liver cancer

Initiated Phase I/II trial (6/14)

Transgene SA (France)

­

Adenovirus-delivered interferon-gamma gene therapy

Advanced malignant melanoma

Initiated Phase I trial (6/22)

Valentis Inc. and Roche Holdings Ltd. (Switzerland)

­

Interleukin-2 gene therapy consisting of a plasmid encoding the human IL-2 gene and a cationic lipid delivery system

Squamous cell carcinoma of the head and neck

Initiated Phase II trial (6/29)

CARDIOVASCULAR

Alteon Inc.

ALT-811

AGE crosslink-breaker; orally active compound that breaks cross-linked advanced glycolysation end products

To reverse deterioration of cardiovascular system seen with aging

Completed initial Phase I trials in the Netherlands (6/2)

Avant Immuno- therapeutics Inc.

CETi-1

Vaccine that induces antibodies against cholesteryl ester transfer protein, which facilitates transfer of cholesterol from high-density lipoprotein to low-density lipoprotein

Prevention or treatment of atherosclerosis

Initiated Phase I trial (6/21)

Avigen Inc.

Coagulin-B

Adeno-associated virus used to deliver Factor IX clotting gene

Hemophilia B

Initiated Phase I trial (6/11)

Chiron Corp.

­

Intravenously administered, retroviral delivered truncated cDNA Factor VIII gene

Hemophilia A

Initiated Phase I trial (6/3)

CV Therapeutics Inc.

Ranolazine

Piperazine acetamide

Chronic stable angina

Data from Phase II trial published in 7/1/99 issue of The AmericanJournal of Cardiology (6/30)

Ranolazine

Piperazine acetamide

Chronic stable angina

Completed enrollment in Phase III monotherapy trial (6/2)

CV Therapeutics Inc.

CVT-510

Selective adenosine A(1) agonist

Atrial arrhythmias

Reported initial results from Phase I trial support initiation of Phase II trial (6/24)

Epix Medical Inc. and Mallinckrodt Inc. (NYSE:MKG)

AngioMARK

Intravascular MRI contrast agent

Detection of aortoiliac occlusive disease

Initiated Phase III trial (6/21)

Selectus Pharmaceuticals Inc.*

­

Esprolol; rapidly acting sublingual beta blocker

Angina pectoris

Initiated enrollment in Phase IIb trial (6/23)

CENTRAL NERVOUS SYSTEM

Celgene Corp.

d-MPH (d-methyl- phenidate)

Chirally pure form of Ritalin

Attention deficit disorder and attention deficit hyperactivity disorder

Completed enrollment in pivotal trials (6/3)

CytoTherapeutics Inc. and Astra- Zeneca Group plc (U.K.)

­

Cell therapy; implant contains bovine adrenal cells that secrete naturally occurring analgesics (catecholamines, opioid peptides); device implanted at base of the spine

Severe, chronic pain in cancer patients

Phase II trial failed to reach statistical significance for efficacy; AstraZeneca terminated collaboration (6/24)

NeoTherapeutics Inc.

Neotrofin (AIT 082)

Small-molecule compound designed to cross blood-brain barrier and enhance nerve cell function by increasing levels of neurotrophic factors

Alzheimer's disease

Presented data from Phase IIa trial at 39th Annual Meeting of the New Clinical Drug Evaluation Unit in Boca Raton, Fla. (6/2)

Neurocrine Biosciences Inc.

NBI-3001

Interleukin-4 fusion toxin that binds with high affinity to IL-4 receptors (infused directly into tumors)

Glioblastoma

Presented data from U.S./German Phase I/II trial at the 50th Annual Meeting of the German Society of Neurosurgery in Munich (6/8)

Novopharma Biotech Inc. (TSE:NVO)

NovoVac-M1

Fully human antibody vaccine intended to provoke immune response to GD2 melanoma antigen

Melanoma

Initiated Phase I/II trial (6/15)

DIABETES

Amylin Pharmaceuticals Inc.

AC2993

Synthetic exendin-4; 39-amino-acid peptide that exhibits antidiabetic activity similar to the mammalian hormone glucagon-like peptide-1

Type II diabetes

Initiated Phase II trial (6/30)

Aradigm Corp. and Novo Nordisk A/S (Denmark; NYSE:NVO)

AERx Diabetes Management System

Insulin delivered via fine aerosol mists that are deposited deep into the lung; handheld electronic inhaler guides patient to breathe correctly and consistently

Type I diabetes

Presented Phase II trial data at the American Diabetes Association's 59th Annual Scientific Sessions in San Diego (ADA) (6/21)

Celtrix Pharmaceuticals Inc.

SomatoKine

IGF BP3 complex; recombinant version of complex formed by insulin-like growth factor-1 and its major binding protein (intravenous administration)

Type I diabetes

Presented Phase IIa trial results at ADA meeting and at the Endocrine Society's 81st Annual Meeting in San Diego (6/21)

Hoechst Marion Roussel (unit of Hoechst AG; Germany)

­

Insulin glargine; long-acting, once-daily insulin analogue

Diabetes

Presented summary of multiple clinical trials at ADA meeting (6/21)

Inhale Therapeutic Systems Inc. and Pfizer Inc. (NYSE:PFE)

­

Dry powder formulation of recombinant insulin; delivered via pulmonary delivery system

Diabetes

Initiated Phase III trial (6/29)

Organogenesis Inc. and Novartis AG (Switzerland)

Apligraf (FDA- approved)

Living human skin equivalent, composed of living human keratinocytes and fibroblasts (epidermis and dermis, isolated from infant foreskins) cultured in a 3-dimensional system

Diabetic foot ulcers

Presented additional data from pivotal trial at the ADA meeting (6/22)

INFECTION

Antex Biologics (OTC BB:ANTX)

Oral vaccine against Campylobacter

Oral, inactivated, whole-cell vaccine, combined with adjuvant

Prevention of Campylobacter infection and related gastroent eritis and diarrhea

Completed Phase II trial (6/16)

Aviron and Wyeth Lederle Vaccines (unit of American Home Products; NYSE: AHP)

FluMist

Nasal spray formulation of influenza vaccine; attenuated, cold-adapted live virus vaccine

Prevention of influenza infection

Completed bridging study (6/9)

BioCryst Pharmaceuticals Inc.

­

Oral inhibitor of influenza neuraminidase

Prevention and treatment of influenza infection

Initiated Phase II trial (6/23)

Dimethaid Research (Canada; TSE:DMX)

­

Dimethysulfoxide-based transdermal delivery agent for undisclosed antifungal drug

Onychomycosis (infection under the toenail)

Initiated pilot study (6/1)

Immunomedics Inc.

LeukoScan

Sulesomab; monoclonal antibody fragment labeled with technetium-99 that binds to white blood cells

Infection imaging of children suspected of having atypical appendicitis

Case presentations made at 46th Annual Meeting of the Society of Nuclear Medicine in Los Angeles (6/9)

Trimeris Inc.

T-20

Antiviral fusion-inhibiting compound (delivered by continuous subcutaneous infusion via pump)

Treatment of HIV as part of combination therapy

Initiated Phase II trial (6/23)

MISCELLANEOUS

Abgenix Inc.

ABX-IL8

Fully human monoclonal antibody that binds to inter-leukin-8 (produced via XenoMouse technology)

Psoriasis

Completed enrollment in Phase I/II trial (6/15)

Alexion Pharmaceuticals Inc.

5G1.1

Humanized single-chain antibody designed to intervene in complement cascade (complement inhibitor)

Systemic lupus

Completed preliminary analysis of Phase I trial (6/15)

Allelix Biopharmaceuticals Inc. (Canada)

ALX-0600

Analogue of naturally occurring peptide GLP2; enhances rate of growth of epithelium of small intestine

Short bowel syndrome

Initiated pilot Phase II trial (6/8)

Alkermes Inc. and Genentech Inc.

Nutropin Depot

Sustained-release formulation of Genentech's recombinant growth hormone based on Alkermes' ProLease injectable delivery system (administered once or twice a month)

Growth hormone deficiency in children

Reported positive Phase III results (6/13)

Cantab Pharmaceuticals plc (U.K.)

TA-CD

Anti-cocaine vaccine consisting of a cocaine derivative coupled with a carrier protein, rCTB, which are together formulated with the adjuvant aluminum hydroxide (alum); administered by intramuscular injection

Neutralization of cocaine's psychoactive effect as a treatment for cocaine addiction

Presented Phase I trial results at 61st Annual Scientific Meeting of the College on Problems of Drug Dependence in Acapulco, Mexico (6/15)

Centocor Inc.

Remicade (FDA- approved)

Infliximab; chimeric monoclonal antibody to tumor necrosis factor-alpha

Rheumatoid arthritis

Presented summary of positive results from Phase III ATTRACT trial (Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy) at the European League Against Rheumatism meeting in Glasgow, Scotland (6/7)

Creative BioMolecules Inc. and Stryker Corp. (NYSE:SYK)

OP-1 Implant

Device that combines genetically engineered bone morphogenic protein (OP-1) with resorbable collagen scaffold that is surgically implanted in bone fractures and defects

Long bone nonunions

Submitted final module of PMA (6/7)

InSite Vision Inc. and Pharmacia and Upjohn Inc. (NYSE:PNU)

ISV-205

Product that inhibits protein product of TIGR gene

Glaucoma

Released Phase II trial results (6/17)

Ligand Pharmaceuticals Inc.

Targretin capsules

Bexarotene; synthetic retinoid analogue that selectively activates retinoid X receptors; oral formulation

Moderate to severe plaque psoriasis

Released interim data from Phase II trial (6/25)

Pharmacyclics Inc.

Lu-Tex/Optrin

Lutetium texaphyrin; light-activated drug delivered intravenously

Age-related macular degeneration

Presented Phase I/II trial data at meeting of European Society of Ophthalmology in Stockholm, Sweden (6/28)

Sensus Drug Development Corp.*

B2036-PEG

Pegvisomant; growth hormone receptor antagonist

Acromegaly

Announced positive Phase III trial data (6/16)